ALTHX Share Price Performance
€2.50
1.99 (386.38%)
Price €2.50
Share Price€2.50
Theranexus Société Anonyme Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
ALTHX Community Narratives
There are no narratives available yet.
Recent ALTHX News & Updates
Theranexus Société Anonyme Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.31
- Gross Margin
- -167.83%
- Net Profit Margin
- -335.32%
- Debt/Equity Ratio
- -152.6%
Theranexus Société Anonyme Competitors
Snowflake Analysis
About ALTHX
- Founded
- 2013
- Employees
- 10
- CEO
- WebsiteView website
Theranexus Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was founded in 2013 and is headquartered in Lyon, France.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
French Market Performance
- 7 Days: -2.2%
- 3 Months: 0.6%
- 1 Year: 2.8%
- Year to Date: 5.1%
Over the last 7 days, the market has dropped 2.2%, driven by a loss of 3.0% in the Consumer Discretionary sector. Overall the market has been flat in the last year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›